185 related articles for article (PubMed ID: 38023710)
21. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
[TBL] [Abstract][Full Text] [Related]
22. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
23. A clear cell renal cell carcinoma inhibiting the response to intravitreal antivascular endothelial growth factor therapy in wet age-related macular disease.
Falcão MS; Vinagre J; Soares P; Lopes JM; Brandão E; Carneiro AM
Case Rep Ophthalmol; 2012 Sep; 3(3):443-51. PubMed ID: 23341823
[TBL] [Abstract][Full Text] [Related]
24. Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD.
Reid CA; Nettesheim ER; Connor TB; Lipinski DM
Sci Rep; 2018 Aug; 8(1):11763. PubMed ID: 30082848
[TBL] [Abstract][Full Text] [Related]
25. Anti-Vascular Endothelial Growth Factor Intravitreal Therapy and Macular Ganglion Cell Layer Thickness in Patients with Neovascular Age-Related Macular Degeneration.
Abdolrahimzadeh S; Gharbiya M; Formisano M; Bertini F; Cerini A; Pacella E
Curr Eye Res; 2019 Sep; 44(9):1000-1005. PubMed ID: 30999772
[No Abstract] [Full Text] [Related]
26. Racial Differences in Age-Related Macular Degeneration and Associated Anti-Vascular Endothelial Growth Factor Intravitreal Injections among Medicare Beneficiaries.
Mahr MA; Hodge DO; Erie JC
Ophthalmol Retina; 2018 Dec; 2(12):1188-1195. PubMed ID: 31047189
[TBL] [Abstract][Full Text] [Related]
27. Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration.
Avaylon J; Lee S; Gallemore RP
Int Med Case Rep J; 2020; 13():145-152. PubMed ID: 32494207
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration.
Yoshida I; Shiba T; Taniguchi H; Takahashi M; Murano T; Hiruta N; Hori Y; Bujo H; Maeno T
Graefes Arch Clin Exp Ophthalmol; 2014 Sep; 252(9):1483-9. PubMed ID: 25030237
[TBL] [Abstract][Full Text] [Related]
29. Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment.
Foss A; Rotsos T; Empeslidis T; Chong V
Ophthalmologica; 2022; 245(3):204-217. PubMed ID: 34695835
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration.
Yamashita M; Matsumoto M; Hayakawa M; Sakai K; Fujimura Y; Ogata N
Sci Rep; 2018 Jan; 8(1):1491. PubMed ID: 29367644
[TBL] [Abstract][Full Text] [Related]
31. Value of Anti-Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration.
Berkowitz ST; Patel S
Ophthalmol Retina; 2021 Apr; 5(4):357-364. PubMed ID: 32818623
[TBL] [Abstract][Full Text] [Related]
32. [Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years].
Bodénès F; Massé H; Lebreton O; Weber M
J Fr Ophtalmol; 2021 May; 44(5):626-631. PubMed ID: 33840491
[TBL] [Abstract][Full Text] [Related]
33. Atypical macular hole formation after Anti-VEGF therapy for neovascular age-related macular degeneration: Coincidence or consequence?
Kayaarasi Ozturker Z; Akca Bayar S; Yaman Pinarci E; Kurt RA; Akkoyun I; Yilmaz G
Arch Soc Esp Oftalmol (Engl Ed); 2021 Sep; 96(9):455-461. PubMed ID: 34479701
[TBL] [Abstract][Full Text] [Related]
34. Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration.
Seong HJ; Park YM; Kim J; Son KJ; Chung EJ
Korean J Ophthalmol; 2022 Oct; 36(5):435-442. PubMed ID: 35989065
[TBL] [Abstract][Full Text] [Related]
35. Elevated YKL-40 serum levels may contribute to wet age-related macular degeneration via the ERK1/2 pathway.
Bin Y; Liu Y; Jiang S; Peng H
FEBS Open Bio; 2021 Nov; 11(11):2933-2942. PubMed ID: 34110111
[TBL] [Abstract][Full Text] [Related]
36. [Intravitreal anti-VEGF injections improve the visual prognosis of wet age related macular degeneration].
Ambresin A; Mantel I
Rev Med Suisse; 2007 Jan; 3(94):137-41. PubMed ID: 17354539
[TBL] [Abstract][Full Text] [Related]
37. Long-term therapeutic effect in nonhuman primate eye from a single injection of anti-VEGF controlled release hydrogel.
Yu Y; Lin X; Wang Q; He M; Chau Y
Bioeng Transl Med; 2019 May; 4(2):e10128. PubMed ID: 31249878
[TBL] [Abstract][Full Text] [Related]
38. Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy.
Kokame GT; deCarlo TE; Kaneko KN; Omizo JN; Lian R
Ophthalmol Retina; 2019 Sep; 3(9):744-752. PubMed ID: 31511169
[TBL] [Abstract][Full Text] [Related]
39. Injectable Anti-Inflammatory Supramolecular Nanofiber Hydrogel to Promote Anti-VEGF Therapy in Age-Related Macular Degeneration Treatment.
Gao H; Chen M; Liu Y; Zhang D; Shen J; Ni N; Tang Z; Ju Y; Dai X; Zhuang A; Wang Z; Chen Q; Fan X; Liu Z; Gu P
Adv Mater; 2023 Jan; 35(2):e2204994. PubMed ID: 36349821
[TBL] [Abstract][Full Text] [Related]
40. [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].
Meyer CH; Helb HM; Eter N
Ophthalmologe; 2008 Feb; 105(2):125-38, 140-2. PubMed ID: 18256841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
